{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:36:40Z","timestamp":1791466600639,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Evidence regarding effectiveness and safety of clozapine once- vs. multiple-daily dosing is limited. We compared demographic and clinical parameters between patients with once- vs. multiple-daily dosing in the Department of Psychiatry and Psychotherapy, University of Regensburg, Germany (AGATE dataset), and the Department of Psychiatry, Lausanne University Hospital, Switzerland, using non-parametric tests. Effectiveness and safety outcomes were available in the AGATE dataset. We performed a systematic review in PubMed\/Embase until February 2022, meta-analyzing studies comparing clozapine once- vs. multiple-daily-dosing. We estimated a pooled odds ratio for adverse drug-induced reactions (ADRs) and meta-analyzed differences regarding clinical symptom severity, age, percentage males, smokers, clozapine dose, and co-medications between patients receiving once- vs. multiple-daily dosing. Study quality was assessed using the Newcastle\u2013Ottawa-Scale. Of 1494 and 174 patients included in AGATE and Lausanne datasets, clozapine was prescribed multiple-daily in 74.8% and 67.8%, respectively. In the AGATE cohort, no differences were reported for the clinical symptoms severity or ADR rate (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Meta-analyzing eight cohorts with a total of 2810 clozapine-treated individuals, we found more severe clinical symptoms (<jats:italic>p<\/jats:italic>\u2009=\u20090.036), increased ADR risk (<jats:italic>p<\/jats:italic>\u2009=\u20090.01), higher clozapine doses (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), more frequent co-medication with other antipsychotics (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), benzodiazepines (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), anticholinergics (<jats:italic>p<\/jats:italic>\u2009=\u20090.039), and laxatives (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) in patients on multiple- vs. once-daily dosing. Of six studies, five were rated as good, and one as poor quality. Patients responding less well to clozapine may be prescribed higher doses multiple-daily, also treated with polypharmacy, potentially underlying worse safety outcomes. Patient preferences and adherence should be considered during regimen selection.<\/jats:p>","DOI":"10.1007\/s00406-022-01542-1","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T08:02:57Z","timestamp":1672300977000},"page":"1567-1578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clozapine once- versus multiple-daily dosing: a two-center cross-sectional study, systematic review and meta-analysis"],"prefix":"10.1007","volume":"273","author":[{"given":"Nazar","family":"Kuzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic M.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Bin","family":"Eap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"de Filippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Homan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Andr\u00e9","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Paulzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"issue":"2","key":"1542_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00004714-199804000-00002","volume":"18","author":"NPV Nair","year":"1998","unstructured":"Nair NPV et al (1998) Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The risperidone study group. J Clin Psychopharmacol 18(2):103\u2013110. https:\/\/doi.org\/10.1097\/00004714-199804000-00002","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1542_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.4088\/JCP.13M08695","volume":"75","author":"H Takeuchi","year":"2014","unstructured":"Takeuchi H et al (2014) Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. J Clin Psychiatry 75(5):506\u2013511. https:\/\/doi.org\/10.4088\/JCP.13M08695","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1542_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/J.EURONEURO.2014.12.008","volume":"25","author":"H Takeuchi","year":"2015","unstructured":"Takeuchi H, Fervaha G, Lee J, Agid O, Remington G (2015) Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. Eur Neuropsychopharmacol 25(3):295\u2013302. https:\/\/doi.org\/10.1016\/J.EURONEURO.2014.12.008","journal-title":"Eur Neuropsychopharmacol"},{"key":"1542_CR4","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20R13503","author":"Y Kikuchi","year":"2021","unstructured":"Kikuchi Y, Shimomura Y, Suzuki T, Uchida H, Mimura M, Takeuchi H (2021) Single versus multiple daily dosing regimens of psychotropic drugs for psychiatric disorders: a systematic review and meta-analysis. J Clin Psychiatry. https:\/\/doi.org\/10.4088\/JCP.20R13503","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1542_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/ACPS.13208","volume":"142","author":"H Takeuchi","year":"2020","unstructured":"Takeuchi H et al (2020) Adherence to clozapine vs. other antipsychotics in schizophrenia. Acta Psychiatr Scand 142(2):87\u201395. https:\/\/doi.org\/10.1111\/ACPS.13208","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"1542_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/J.MEHY.2013.11.043","volume":"82","author":"RM Procyshyn","year":"2014","unstructured":"Procyshyn RM, Vila-Rodriguez F, Honer WG, Barr AM (2014) Clozapine administered once versus twice daily: does it make a difference? Med Hypotheses 82(2):225\u2013228. https:\/\/doi.org\/10.1016\/J.MEHY.2013.11.043","journal-title":"Med Hypotheses"},{"issue":"12","key":"1542_CR7","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1007\/S11095-008-9787-9","volume":"25","author":"S Sahin","year":"2008","unstructured":"Sahin S, Benet LZ (2008) The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 25(12):2869\u20132877. https:\/\/doi.org\/10.1007\/S11095-008-9787-9","journal-title":"Pharm Res"},{"issue":"9","key":"1542_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/ARCHPSYC.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45(9):789\u2013796. https:\/\/doi.org\/10.1001\/ARCHPSYC.1988.01800330013001","journal-title":"Arch Gen Psychiatry"},{"key":"1542_CR9","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18COM12123","author":"JM Kane","year":"2019","unstructured":"Kane JM et al (2019) Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. https:\/\/doi.org\/10.4088\/JCP.18COM12123","journal-title":"J Clin Psychiatry"},{"key":"1542_CR10","unstructured":"\u201cCLOZARIL\u00ae Product Monograph.\u201d https:\/\/www.novartis.ca\/sites\/www.novartis.ca\/files\/clozaril_scrip_e.pdf. Accessed 25 Apr 2022"},{"key":"1542_CR11","unstructured":"\u201cCLOZARIL\u00ae Prescribing Information.\u201d https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/019758s062lbl.pdf. Accessed 25 Apr 2022"},{"key":"1542_CR12","unstructured":"\u201cCLOZARIL\u00ae Prescribing Information.\u201d https:\/\/www.info.pmda.go.jp\/go\/pack\/1179049F1021_1_20\/. Accessed 25 Apr 2022"},{"issue":"3","key":"1542_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/ACPS.12593","volume":"134","author":"H Takeuchi","year":"2016","unstructured":"Takeuchi H et al (2016) Clozapine administration in clinical practice: once-daily versus divided dosing. Acta Psychiatr Scand 134(3):234\u2013240. https:\/\/doi.org\/10.1111\/ACPS.12593","journal-title":"Acta Psychiatr Scand"},{"key":"1542_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001492","author":"K Kitagawa","year":"2021","unstructured":"Kitagawa K et al (2021) Clozapine once-daily versus divided dosing regimen a cross-sectional study in Japan at 2 psychiatric hospitals in. J Clin Psychopharmacol. https:\/\/doi.org\/10.1097\/JCP.0000000000001492","journal-title":"J Clin Psychopharmacol"},{"key":"1542_CR15","unstructured":"\u201cArbeitsgemeinschaft Arzneimitteltherapie bei psychiatrischen Erkrankungen e.V. \u2013 mit der Deutschen Gesellschaft f\u00fcr Psychiatrie, Psychotherapie , Psychosomatik und Nervenheilkunde (DGPPN) kooperierende Fachgesellschaft.\u201d https:\/\/www.amuep-agate.de\/cms\/. Accessed 25 Apr 2022"},{"issue":"Suppl 1","key":"1542_CR16","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/SJA.SJA_543_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S (2019) The STROBE guidelines. Saudi J Anaesth 13(Suppl 1):S31. https:\/\/doi.org\/10.4103\/SJA.SJA_543_18","journal-title":"Saudi J Anaesth"},{"key":"1542_CR17","unstructured":"\u201cECDEU assessment manual for psychopharmacology (1976 edition) | Open Library.\u201d https:\/\/openlibrary.org\/books\/OL24341821M\/ECDEU_assessment_manual_for_psychopharmacology. Accessed 25 Apr 2022"},{"issue":"7","key":"1542_CR18","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD (2007) The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 4(7):28","journal-title":"Psychiatry (Edgmont)"},{"key":"1542_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/J.1600-0447.1987.TB10566.X","volume":"334","author":"O Lingj\u00e6rde","year":"1987","unstructured":"Lingj\u00e6rde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1\u2013100. https:\/\/doi.org\/10.1111\/J.1600-0447.1987.TB10566.X","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"01","key":"1542_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1055\/S-2005-862617","volume":"38","author":"W Bader","year":"2005","unstructured":"Bader W, Melchner D, Nonenmacher T, Haen E (2005) Determination of five commonly used antipsychotics in human serum by high performance-liquid chromatography (HPLC) and electrochemical detection. Pharmacopsychiatry 38(01):4. https:\/\/doi.org\/10.1055\/S-2005-862617","journal-title":"Pharmacopsychiatry"},{"issue":"1\u20132","key":"1542_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000135641","volume":"57","author":"D Fischer-Barnicol","year":"2008","unstructured":"Fischer-Barnicol D et al (2008) Typical and Atypical Antipsychotics \u2013 The Misleading Dichotomy. Neuropsychobiology 57(1\u20132):80\u201387. https:\/\/doi.org\/10.1159\/000135641","journal-title":"Neuropsychobiology"},{"key":"1542_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/J.CHROMA.2012.12.071","volume":"1292","author":"N Ansermot","year":"2013","unstructured":"Ansermot N, Brawand-Amey M, Kottelat A, Eap CB (2013) Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. J Chromatogr A 1292:160\u2013172. https:\/\/doi.org\/10.1016\/J.CHROMA.2012.12.071","journal-title":"J Chromatogr A"},{"key":"1542_CR23","unstructured":"\u201cWMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Subjects \u2013 WMA \u2013 The World Medical Association.\u201d https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/. Accessed 25 Apr 2022"},{"key":"1542_CR24","doi-asserted-by":"publisher","unstructured":"G. Schwarzer, J. R. Carpenter, and G. R\u00fccker, \u201cMeta-Analysis with R,\u201d 2015, Doi: https:\/\/doi.org\/10.1007\/978-3-319-21416-0","DOI":"10.1007\/978-3-319-21416-0"},{"issue":"15","key":"1542_CR25","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/JAMA.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008\u20132012. https:\/\/doi.org\/10.1001\/JAMA.283.15.2008","journal-title":"JAMA"},{"issue":"3","key":"1542_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/JCP.0000000000001384","volume":"41","author":"LD Leclerc","year":"2021","unstructured":"Leclerc LD et al (2021) A chart audit study of clozapine utilization in early psychosis. J Clin Psychopharmacol 41(3):275\u2013280. https:\/\/doi.org\/10.1097\/JCP.0000000000001384","journal-title":"J Clin Psychopharmacol"},{"key":"1542_CR27","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2147\/NDT.S312095","volume":"17","author":"R de Filippis","year":"2021","unstructured":"de Filippis R et al (2021) Clozapine management in schizophrenia inpatients: a 5-year prospective observational study of its safety and tolerability profile. Neuropsychiatr Dis Treat 17:2141\u20132150. https:\/\/doi.org\/10.2147\/NDT.S312095","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1542_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-13-154\/COMMENTS","volume":"13","author":"R Herzog","year":"2013","unstructured":"Herzog R, \u00c1lvarez-Pasquin MJ, D\u00edaz C, del Barrio JL, Estrada JM, Gil \u00c1 (2013) Are healthcare workers intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 13(1):1\u201317. https:\/\/doi.org\/10.1186\/1471-2458-13-154\/COMMENTS","journal-title":"BMC Public Health"},{"issue":"3","key":"1542_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"issue":"7414","key":"1542_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/BMJ.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/BMJ.327.7414.557","journal-title":"BMJ"},{"issue":"7109","key":"1542_CR31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/BMJ.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634. https:\/\/doi.org\/10.1136\/BMJ.315.7109.629","journal-title":"BMJ"},{"key":"1542_CR32","unstructured":"\u201cClozapin Beipackzettel in der Schweiz.\u201d https:\/\/compendium.ch\/product\/1384598-clozapin-mepha-tabl-25-mg\/mpro. Accessed 27 Mar 2022"},{"issue":"3","key":"1542_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/S40262-020-00944-5","volume":"60","author":"G Schoretsanitis","year":"2021","unstructured":"Schoretsanitis G, Kuzin M, Kane JM, Hiemke C, Paulzen M, Haen E (2021) Elevated clozapine concentrations in clozapine-treated patients with hypersalivation. Clin Pharmacokinet 60(3):329\u2013335. https:\/\/doi.org\/10.1007\/S40262-020-00944-5","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1542_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/S00213-020-05746-Y","volume":"238","author":"MSA Tan","year":"2021","unstructured":"Tan MSA, Honarparvar F, Falconer JR, Parekh HS, Pandey P, Siskind DJ (2021) A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. Psychopharmacology 238(3):615\u2013637. https:\/\/doi.org\/10.1007\/S00213-020-05746-Y","journal-title":"Psychopharmacology"},{"issue":"1","key":"1542_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/10398562211042368","volume":"30","author":"V Sazhin","year":"2022","unstructured":"Sazhin V, Pushkal P (2022) Predictors of laxative use in inpatients with schizophrenia on clozapine. Australas Psychiatry 30(1):105\u2013109. https:\/\/doi.org\/10.1177\/10398562211042368","journal-title":"Australas Psychiatry"},{"key":"1542_CR36","unstructured":"DGPPN e.V. (Hrsg.) f\u00fcr die Leitliniengruppe, \u201cS3-Leitlinie Schizophrenie. Langfassung, 2019, Version 1.0, zuletzt ge\u00e4ndert am 15. M\u00e4rz 2019,\u201d https:\/\/www.awmf.org\/, Mar. 15, 2019. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/038-009l_S3_Schizophrenie_2019-03.pdf. Accessed 5 Dec 2021"},{"issue":"7","key":"1542_CR37","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1177\/0269881108100320","volume":"24","author":"J Nielsen","year":"2010","unstructured":"Nielsen J, Dahm M, Lublin H, Taylor D (2010) Psychiatrists\u2019 attitude towards and knowledge of clozapine treatment. J Psychopharmacol 24(7):965\u2013971. https:\/\/doi.org\/10.1177\/0269881108100320","journal-title":"J Psychopharmacol"},{"issue":"6","key":"1542_CR38","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1192\/BJP.BP.111.105833","volume":"201","author":"OD Howes","year":"2012","unstructured":"Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D (2012) Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 201(6):481\u2013485. https:\/\/doi.org\/10.1192\/BJP.BP.111.105833","journal-title":"Br J Psychiatry"},{"key":"1542_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/J.PSYCHRES.2017.01.064","volume":"250","author":"B Yoshimura","year":"2017","unstructured":"Yoshimura B, Yada Y, So R, Takaki M, Yamada N (2017) The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res 250:65\u201370. https:\/\/doi.org\/10.1016\/J.PSYCHRES.2017.01.064","journal-title":"Psychiatry Res"},{"key":"1542_CR40","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/J.PSYCHRES.2018.06.070","volume":"268","author":"P Shah","year":"2018","unstructured":"Shah P et al (2018) The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. Psychiatry Res 268:114\u2013122. https:\/\/doi.org\/10.1016\/J.PSYCHRES.2018.06.070","journal-title":"Psychiatry Res"},{"issue":"4","key":"1542_CR41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/ACPS.12954","volume":"138","author":"C Okhuijsen-Pfeifer","year":"2018","unstructured":"Okhuijsen-Pfeifer C et al (2018) Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr Scand 138(4):281\u2013288. https:\/\/doi.org\/10.1111\/ACPS.12954","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"1542_CR42","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/BCPT.13421","volume":"127","author":"M Kuzin","year":"2020","unstructured":"Kuzin M et al (2020) Pharmacokinetic interactions between clozapine and sertraline in smokers and non-smokers. Basic Clin Pharmacol Toxicol 127(4):303\u2013308. https:\/\/doi.org\/10.1111\/BCPT.13421","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-022-01542-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-022-01542-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-022-01542-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T05:02:58Z","timestamp":1693285378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-022-01542-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1542"],"URL":"https:\/\/doi.org\/10.1007\/s00406-022-01542-1","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"6 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ekkehard Haen received speaker\u2019s or consultancy fees from Servier, Novartis, and Janssen-Cilag. He is managing director of AGATE, a non-profit working group to improve drug safety and effectiveness in the treatment of psychiatric diseases. Hiroyoshi Takeuchi has grants from Daiichi Sankyo and Novartis Pharma; speaker\u2019s fees from EA Pharma, Kyowa, Janssen, Lundbeck, Meiji Seika Pharma, Otsuka, Sumitomo Pharma, Takeda, and Yoshitomiyakuhin; and consultant fees from Janssen, Mitsubishi Tanabe Pharma, and Sumitomo Pharma. Chin-Bin Eap received honoraria for conferences or teaching CME courses from Forum pour la formation m\u00e9dicale, Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller in the past 3\u00a0years. John M. Kane has been a consultant and\/or advisor to or has received honoraria from Alkermes, Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Dainippon Sumitomo, IntraCellular Therapies, Janssen, Lundbeck, Merck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Saladex, Sunovion, Takeda and Teva. He is a shareholder of LB Pharma, and The Vanguard Research Group. Michael Paulzen has received speaker\u2019s fees from Neuraxpharm and Lundbeck. Marc-Andr\u00e9 Roy has received grants from Otsuka-Lundbeck Alliance, Janssen, Sunovion, AbbVie and Mylan. Georgios Schoretsanitis has served as a consultant for HLS Therapeutics and Thermo Fisher and has received speaker's fees from HLS Therapeutics. All other authors report no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}